Zhong Guo Zheng Quan Bao·2025-09-04 18:55Core Viewpoint - Fosun Pharma has transformed from a generic drug company to a high-level innovation-driven enterprise, focusing on innovation and global expansion, reflecting the shift of China's pharmaceutical industry from follower to leader [1] Group 1: Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan and a net profit of 1.702 billion yuan, representing a year-on-year growth of 38.96% [1] - Revenue from innovative drugs exceeded 4.3 billion yuan, marking a year-on-year increase of 14.26%, driven by product structure optimization and sales growth [2] Group 2: Innovation Strategy - The company emphasizes innovation as its core development engine, focusing on unmet clinical needs and core therapeutic areas, while enhancing R&D capabilities and efficiency [1][2] - Fosun Pharma has approved 4 innovative drugs and 57 generic drugs during the reporting period, with nearly 20 innovative drug clinical trials approved by regulatory agencies [2] Group 3: Global Expansion - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for approximately 28.07% of total revenue, with a focus on establishing a commercial presence in the U.S. market [3] - The company has built a mature commercialization system, with over 1,000 personnel in its overseas commercialization team, and aims to deepen international cooperation [4] Group 4: Strategic Initiatives - Fosun Pharma plans to launch a new A+H share equity incentive plan, with core performance indicators focusing on net profit and innovative drug revenue [2] - The company adheres to the 4IN strategy: Innovation, Internationalization, Intelligentization, and Integration, aiming to accelerate progress in these areas [6]